Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Mullard, A. Small molecules against RNA targets attract big backers. Nat Rev Drug Discov 16, 813–815 (2017). https://doi.org/10.1038/nrd.2017.239
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.239
- Springer Nature Limited
This article is cited by
-
RNA-based therapeutics: an overview and prospectus
Cell Death & Disease (2022)
-
Noncoding RNAs regulate alternative splicing in Cancer
Journal of Experimental & Clinical Cancer Research (2021)
-
Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting
Signal Transduction and Targeted Therapy (2020)